Teriflunomide for the Treatment of Relapsing Multiple Sclerosis

No abstract is available for this paper.

• Publication year

  2013

• Venue

  The Annals of Pharmacotherapy

• Publication date

  2013-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1060028013500647PMID 24259730
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Leflunomide in dialysis patients with rheumatoid arthritis—a pharmacokinetic study

  2013cited by this paper
• Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

  2012cited by this paper
• Teriflunomide added to interferon-β in relapsing multiple sclerosis

  2012influential reference
• Emerging oral immunomodulating agents - focus on teriflunomide for the treatment of multiple sclerosis.

  2012cited by this paper
• Teriflunomide for multiple sclerosis.

  2012cited by this paper
• Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

  2011influential reference
• Pathophysiology of multiple sclerosis and the place of teriflunomide

  2011influential reference
• Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

  2010cited by this paper
• Possible clinical outcome measures for clinical trials in patients with multiple sclerosis

  2010cited by this paper
• Birth outcomes in women who have taken leflunomide during pregnancy.

  2010cited by this paper
• A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

  2010cited by this paper
• Impact of Adherence to Interferons in the Treatment of Multiple Sclerosis

  2010cited by this paper
• Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up.

  2010cited by this paper
• Multiple Sclerosis

  2007influential reference
• A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

  2006influential reference
• Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation.

  2005cited by this paper
• Clinical Pharmacokinetics of Leflunomide

  2002influential reference
• Mechanism of action for leflunomide in rheumatoid arthritis.

  1999influential reference
• The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.

  1996cited by this paper
• The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

  1989cited by this paper

• Hepatotoxicity of Drugs Used in Multiple Sclerosis, Diagnostic Challenge, and the Role of HLA Genotype Susceptibility

  2023cites this paper
• In vivo detection of teriflunomide-derived fluorine signal during neuroinflammation using fluorine MR spectroscopy

  2021cites this paper
• Carbon-13 Synthesis and NMR Spectroscopic Geometric Isomer Evaluation to Support the Filing of Teriflunomide.

  2020cites this paper
• Reduced disease severity following therapeutic treatment with angiotensin 1-7 in a mouse model of multiple sclerosis.

  2019cites this paper
• Synthesis, structure-activity relationship and binding mode analysis of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase.

  2017cites this paper
• Update on disease-modifying therapies for multiple sclerosis

  2017cites this paper
• Inhibition by Teriflunomide of Erythrocyte Cell Membrane Scrambling Following Energy Depletion, Oxidative Stress and Ionomycin

  2016cites this paper
• The blood-brain barrier in multiple sclerosis: microRNAs as key regulators.

  2015cites this paper
• Teriflunomide (Aubagio®) for the treatment of multiple sclerosis.

  2014cites this paper
• The new therapeutic landscape in multiple sclerosis: exciting times and new perspectives.

  2014cites this paper
• Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients

  2014cites this paper